血管内皮生长因子B(VEGFB)多克隆抗体

Polyclonal Antibody to Vascular Endothelial Growth Factor B (VEGFB)

VEGF-B; VEGFL; VRF; VEGF-Related Factor

  • 血管内皮生长因子B(VEGFB)多克隆抗体 产品包装(模拟)
  • 血管内皮生长因子B(VEGFB)多克隆抗体 产品包装(模拟)
  • 血管内皮生长因子B(VEGFB)多克隆抗体 DAB staining on IHC-P; Samples: Bovine Kidney Tissue; Primary Ab: 20µg/ml Rabbit Anti-Bovine VEGFB Antibody Second Ab: 2µg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody (Catalog: SAA544Rb19)
  • PAA144Bo02.jpg Western Blot; Sample: Bovine Liver lysate Primary Ab: 1μg/ml Rabbit Anti-Bovine VEGFB Antibody Secon
  • Certificate 通过ISO 9001、ISO 13485质量体系认证

特异性

该抗体是针对VEGFB的兔多克隆抗体。在免疫组织化学染色和免疫印迹实验中能识别VEGFB。

用法

Western blotting: 0.5-2µg/mL
Immunohistochemistry: 5-20µg/mL
Immunocytochemistry: 5-20µg/mL
Optimal working dilutions must be determined by end user.

储存

经常使用则4°C保存。-20°C保存不超过两年。避免反复冻融。

稳定性

热稳定性以损失率显示。损失率是由加速降解试验决定，具体方法如下：在37°C孵育48小时，没有显著的降解或者沉淀产生。保质期内，在适当的条件下存储，损失率低于5%。

赠品

相关产品

编号 适用物种：Bos taurus; Bovine (Cattle，牛) 应用(仅供研究使用，不用于临床诊断！)
RPA144Bo02 血管内皮生长因子B(VEGFB)重组蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
RPA144Bo01 血管内皮生长因子B(VEGFB)重组蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
PAA144Bo01 血管内皮生长因子B(VEGFB)多克隆抗体 WB; IHC; ICC; IP.
PAA144Bo02 血管内皮生长因子B(VEGFB)多克隆抗体 WB; IHC; ICC; IP.

参考文献

杂志 参考文献
International Journal of Cardiology Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment-elevation myocardial infarction. [PubMed: 22459379]
Applied Sciences-Basel Assessment of annexin A5 and annexin A2 levels as biomarkers for pre-eclampsia: A pilot study [pubmed:29099033]
Journal of Endocrinological Investigation Plasma vascular endothelial growth factor B levels are increased in patients with newly diagnosed type 2 diabetes mellitus and associated with the first phase of glucose-stimulated insulin secretion function of β-cell [10.1007/s40618-017-0677-z]
EXCLI Journal Plasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunction []
Cancer Chemother Pharmacol Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors [34164713]
留言咨询